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Background: Postpartum follow up of women who have been found to have gestational diabetes during
pregnancy is essential because of the strong association of gestational diabetes with subsequent type 2 diabetes.
Postal reminders have been shown to increase significantly attendance for oral glucose tolerance testing
postpartum. It is possible that a short message service (text) reminder system may also be effective. This trial aims
to assess whether a text message reminder system for women who have experienced gestational diabetes in their
index pregnancy will increase attendance for oral glucose tolerance testing within six months after birth.
Methods/Design: Design: Single centre (Women’s and Children’s Hospital, South Australia), parallel group
randomised controlled trial.
Inclusion criteria: Women diagnosed with gestational diabetes in their index pregnancy (oral glucose tolerance test
with fasting glucose ≥ 5.5 mmol/L and/or two hour glucose ≥ 7.8 mmol/L), with access to a mobile phone, whose
capillary blood glucose profile measurements prior to postnatal discharge are all normal (fasting glucose < 6.0 mmol/L,
postprandial glucoses < 8.0 mmol/L).
Exclusion criteria: Pregestational diabetes mellitus, triplet/higher order multiple birth or stillbirth in the index pregnancy,
requirement for interpreter.
Trial entry and randomisation: Allocation to intervention will be undertaken using a telephone randomisation service
(computer-generated random number sequence generation, with balanced variable blocks, and stratification by insulin
requirement).
Study groups: Women in the intervention group will receive a text reminder to attend for an oral glucose tolerance test
at 6 weeks postpartum, with further reminders at 3 months and 6 months if they do not respond to indicate test
completion. Women in the control group will receive a single text message reminder at 6 months postpartum.
Blinding: Baseline data collection will be undertaken blinded. Blinding of participants and blinded collection of primary
outcome data will not be possible for this study.
Primary study outcome: Attendance for the oral glucose tolerance test within 6 months postpartum.
Sample size: 276 subjects will be required to show an 18% absolute increase in the rate of attendance (α=0.05 two
tailed, β=80%, 5% loss to follow up) from 37% to 55% in the intervention group.
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Discussion: Given the heightened risk of impaired glucose tolerance and type 2 diabetes in women who have had
gestational diabetes, ensuring the highest possible rate of attendance for postpartum glucose tolerance testing, so that
early diagnosis and intervention can occur, is important. A text message reminder system may prove to be an effective
method for achieving improved attendance for such testing. This randomised controlled trial will assess whether such
a system will increase rates of attendance for postpartum oral glucose tolerance testing in women who have
experienced gestational diabetes.
Trial Registration: Australian New Zealand Clinical Trials Registry - ACTRN12612000621819
Keywords: Gestational diabetes mellitus, Reminder system, SMS text reminder, Randomised controlled trial,
Postpartum care, Oral glucose tolerance test, Type 2 diabetes mellitusBackground
Introduction
Gestational diabetes mellitus (GDM) has been defined as
carbohydrate intolerance of variable severity with onset or
first recognition during pregnancy [1]. GDM affects 5% of
pregnancies in Australia, and the prevalence of GDM is
likely to rise with increases in maternal age and obesity [2].
Women who have had GDM are at higher risk for develop-
ment of type 2 diabetes mellitus (DM) in the future com-
pared with women who have had normal blood glucose
values during pregnancy, as well as being at increased risk
of GDM in future pregnancies [3-7]. Therefore, many clin-
ical practice guidelines recommend screening for type 2
DM and impaired glucose tolerance in the postpartum
period [8-13]. Such follow up is important, given the well-
documented risks to women and their babies resulting
from type 2 DM and GDM [14], the availability of inter-
ventions for prevention of type 2 DM and recurrent GDM
such as lifestyle changes, use of metformin, and encourage-
ment of breastfeeding [15], and because direct medical
costs increase greatly with progression from impaired glu-
cose tolerance to type 2 DM with complications [16]. How-
ever, follow up rates for GDM tend to be sub-optimal and
need to be improved [17]. Increasing the rate of follow up
with an oral glucose tolerance test (OGTT) is important,
given that it is the most sensitive test for detection of im-
paired glucose tolerance and type 2 DM within 6 months
postpartum [18].
Reminder systems for increasing postpartum follow up
of GDM
Reminder systems have been used to improve healthcare
with positive results, and some research studies have
assessed the effect of reminders on increasing attendance
for follow up of GDM. For example, implementation of a
postpartum patient reminder system for women who had
experienced GDM into routine care at two hospital sites
in Canada (The Ottawa Hospital, General Campus and the
Queensway Carleton Hospital) resulted in higher rates of
completion of oral glucose tolerance testing by 6 months
postpartum, with a rate of 28% (41/145) compared with14% (16/117 women) in the site where reminders were not
used (The Ottawa Hospital, Civic Campus) (p = 0.01) [19].
However, the rate of completion in both sites where re-
minders were used was considerably lower than the rates of
OGTT completion observed in the randomised controlled
trial (RCT) of postal reminders previously conducted by
the same team at The Ottawa Hospital in Canada [20]. In
the RCT, OGTTcompletion rates were 60% (49/81 women)
in the physician and patient reminder group, 55% (42/76
women) in the patient-only reminder group, 52% (16/31) in
the physician-only reminder group and 14% (5/35 women)
in the group with no reminders sent (p < 0.05). It should be
noted that OGTT completion was measured up until six
months postpartum in the implementation study, com-
pared with up to one year postpartum in the RCT.
A small number of non-randomised studies have ex-
amined reminder systems for postpartum blood glucose
testing in women who have experienced GDM. A Finnish
prospective observational study found that a phone call re-
minder by a nurse increased rates of postpartum oral glu-
cose tolerance testing at one year after birth (odds ratio
13.4, 95% confidence interval 4.6–38.1) [21]. Another study
examined the efficacy of a checklist as a physician reminder
for increasing postpartum screening for type 2 DM in
women who had GDM at the Endocrine Obstetrics Clinic
of the Women’s College Hospital in Toronto, Canada. In
this study, retrospective chart review revealed that use of
the reminder checklist for physicians was associated with a
3 fold increase in odds of a woman being screened with an
OGTT, as measured at ≥ 6 months postpartum (odds ratio
2.99, 95% confidence interval 1.84–4.85) [22].
Following on from a previous study investigating trends
in postpartum glucose test ordering by clinicians and
completion by women (with recent GDM) that found
increasing but suboptimal rates at Kaiser Permanente
Northwest (KPNW, a large non-profit health organisa-
tion in western Oregon and Washington state) [23], an-
other study at KPNW examined the efficacy of several
interventions aimed at increasing the proportion of post-
partum glucose test ordering by clinicians and test com-
pletion by women (including revising the nursing protocol
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medical record system, educating clinical staff and provid-
ing additional reminders to women who did not complete
the test within 3 months of delivery) [24]. Orders for post-
partum glucose screening increased from 77% of (155/200)
women in the pre-implementation period, to 89% (159/
179) in the post-implementation period (p = 0.004), and
completion of postpartum glucose screening increased from
60% (pre-implementation) to 72% (post-implementation)
(hazard ratio, 1.37; 95% confidence interval, 1.07–1.75).
Postpartum reminders for GDM follow up in Australia
The South Australian Gestational Diabetes Recall Regis-
ter was established in July 2002 [25]. This register sent a
reminder letter at 15 months after birth to women who
had experienced GDM to encourage oral glucose tolerance
testing. A study examining the efficacy of the register
found that, of the 429 women who had been sent their first
reminder letter (at 15 months), 56% had undertaken a
glucose test for diabetes (response rate 46%) [25]. There
was considerable variation in the rate of recruitment of
eligible women to the register, with a nadir of 27% in 2006,
and a peak of 72% in 2003. The authors of this study spec-
ulated that reasons for this variability in recruitment rates
may have included time constraints during appointments,
change in staff, and differences in staff efforts to recruit to
the register. The South Australian register has now been
replaced by a national register, the National Gestational
Diabetes Register [26]. Women resident in Australia and
eligible for a Medicare card are recruited to this register at
the time of registering for the National Diabetes Services
Scheme (NDSS) following a diagnosis of GDM, and the
register sends a follow-up reminder letter to such women
to visit a general practitioner to arrange an OGTT at 12–
16 weeks after the expected due date (provided to the
register at the time of registration) and an information
booklet called Life after Gestational Diabetes.
Short message service (SMS) reminders – the reminders
of the future?
In Australia in 2011, there were at least 28 million mobile
phone subscriptions (i.e. 6 million more subscriptions than
people) [27]. With the very high rate of mobile phone
usage, it is likely that almost all women of reproductive
age have access to mobile phones. Given the high rate of
mobile phone use in Australia, and the low cost of SMS
messages, a reminder system that utilises SMS technology
might prove to be a cost-effective way of increasing the
number of women in Australia with a recent history of
GDM, who could then be prompted to undertake oral glu-
cose tolerance testing in the postpartum period. Several
studies in other areas of health care have indicated that
SMS reminders can increase appointment attendance rates
[28-31]. This potential to increase rates of attendance maytranslate into increased rates of oral glucose tolerance
testing in the postpartum period for women who have
had GDM.
Aims and objectives
The primary aim of this RCT is to determine whether an
SMS reminder system will significantly increase atten-
dance for oral glucose tolerance testing by 6 months post-
partum in women who have recently experienced GDM.
Hypotheses
The primary hypothesis is that a SMS reminder system
for women who have recently had GDM will increase
the number of women who complete oral glucose toler-
ance testing by 6 months postpartum.
Methods/Design
Ethics statement
Ethics approval was obtained from the Women’s and
Children’s Health Network Human Research Ethics Com-
mittee (REC2200/8/2015).
Study design
Single centre (Women’s and Children’s Hospital, South
Australia), parallel group randomised controlled trial.
Inclusion criteria
Women diagnosed with GDM in their index pregnancy
(positive 75 g OGTT with fasting glucose ≥ 5.5 mmol/L
and/or two hour glucose ≥ 7.8 mmol/L), with access to
a personal mobile phone, whose capillary blood glucose
profile measurements prior to hospital discharge after giv-
ing birth are normal (fasting blood glucose < 6.0 mmol/L
and 2 hour postprandial blood glucoses < 8.0 mmol/L),
who provide written, informed consent, will be included
in the trial.
Exclusion criteria
Pregestational diabetes mellitus, triplet/higher order
multiple birth or stillbirth in the index pregnancy or re-
quirement for interpreter.
Trial entry
Women who are potentially eligible for the study will be
approached in the postnatal ward, counselled and given
the study information sheet. They will be entered into the
trial if they give written consent and have normal blood
glucose profile results prior to discharge from hospital.
Study groups and management
Eligible women will be randomised into one of two study
groups: either the ‘6 week (intervention) group’ or the
‘6 month (control) group’.
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Randomisation will be carried out using a telephone
randomisation service. The randomisation schedule has
balanced variable blocks and has been prepared by an
investigator not involved in recruitment or clinical care.
Randomisation will be stratified by antenatal require-
ment for drug therapy to treat GDM.
Treatment schedules
Intervention (6 week reminder) group
Women in the intervention group will be sent a SMS
reminder at six weeks after the birth of their baby: “Hi
(Participant Name),This is a reminder from the DIAMIND
study team for you to have your oral glucose tolerance test
for type 2 diabetes. Please let us know when you have done
the test, and what the results were by texting us on (study
number) or emailing us at (study email address) - Thanks
for participating and best wishes”. If the participant re-
sponds to say she has completed the test, no further text
reminders will be sent. If not, a further text reminder will
be sent at three and six months (same message).
Control (6 month reminder) group
Women in the control group will receive no text re-
minders for the first 6 months of the study period. A
single text message reminder (same text as for interven-
tion group) will be sent to these women at 6 months
postpartum (measured from date of birth of baby).
Primary study outcomes
Oral glucose tolerance test undertaken by 6 months
postpartum
Secondary study outcomes
Fasting blood glucose test undertaken by 6 months
postpartum




Baseline data will be collected to assess the similarity
between the two groups in terms of factors that may in-
fluence attendance for postpartum oral glucose tolerance
testing. At trial entry, information will be collected on
demographic characteristics of the participants as well as
smoking history, current BMI at booking and previous
pregnancy outcomes. With regards to GDM, women will
be asked whether or not they were given the opportunity
to join the National Diabetes Services Scheme (NDSS)
and therefore the National Gestational Diabetes Register,
whether they joined, and where they intend to have their
postpartum OGTT completed. Data regarding control of
GDM (dietary control only or requirement for metforminor insulin), diagnostic OGTT date and results, and com-
plications at birth relating to GDM (requirement for in-
duction, caesarean section, perineal injury, blood loss) will
also be collected.
Baseline data relating to the health of the newborn(s)
will be collected: singleton or twin, birth order (if twin),
gestational age at birth, birth weight (grams), time of birth,
gender, Apgar scores, mode of birth (normal vaginal birth,
operative vaginal birth, caesarean section), nerve palsy,
bone fracture, newborn hypoglycaemia (plasma glucose
≤ 2.0 mmol/L), neonatal intensive care admission, respira-
tory distress syndrome, neonatal jaundice requiring photo-
therapy, and death prior to first discharge.
The following information will be collected at hospital
discharge: breastfeeding status (given the link between
breastfeeding and reduced risk of type 2 DM [32,33], as
well as the possible influence that breastfeeding may
have on the mother’s ability to attend for oral glucose
tolerance testing [34]), mention of GDM in the problem
list of the discharge summary and whether or not follow
up oral glucose tolerance testing was recommended in
the discharge summary.
Outcome data collection: 6 months postpartum
All women in the study will be asked to complete a
questionnaire at 6 months after the birth of the baby
either by post or by email (using Survey Monkey), de-
pending on their expressed preference at trial entry, to
ascertain whether an OGTT was undertaken within the
first 6 months, or whether a fasting blood glucose or
glycated haemoglobin (HbA1c) test was used instead.
The questionnaire also asks for the date and results of
these tests, where known. The date and results of the
OGTT will be confirmed using the hospital clinical in-
formation system, or by contact with the participant’s
general practitioner, where necessary. The questionnaire
also examines women’s attitudes towards the OGTT, as
well as reasons for not being able to undertake the test,
if applicable. Where questionnaires are not returned
within 2 weeks, participants will be contacted by tele-
phone, and then again in another 2 weeks if the question-
naires are still not received by the study team. During this
telephone contact, participants will be asked whether or
not they have completed an OGTT within the six months
since they gave birth.
Sample size
The baseline rate of OGTT uptake used in the sample
size calculation for the proposed trial is 37%; this rate is
at the lower end of the range in the recent review by Tovar
and colleagues (2011) [17]. Using a figure from the lower
end of this range is a sound estimate, given that the health
centres in the study had reminder systems in place, and
that some results came from surveys with moderately low
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tational Diabetes Mellitus Recall Register indicates that
the actual rate may be somewhere between 26 and 56
percent [25].
The Stata version 10.0 sample size calculator has been
used to calculate the target sample size.
The figures entered were:
▪ baseline uptake of postnatal OGTT 37%
▪ projected 18% absolute improvement to 55% (48%
relative increase)
▪ power 80%
▪ significance (two-tailed) 5%
This resulted in a calculation that the study will re-
quire 262 women (131 in each arm). With a predicted
up to 5% loss to follow up, 276 women will be required.
Analyses and reporting of results
Baseline characteristics of all randomised women will be
compared descriptively between the study groups. Out-
come comparisons will be made according to the treatment
allocation at randomisation on an ‘intention to treat’ basis.
Categorical variables will be reported as risk ratios with cor-
responding 95% confidence intervals. Continuous outcomes
will be reported as mean (and standard deviation) for nor-
mally distributed results, or median (interquartile range) for
results which are not normally distributed. All model as-
sumptions will be assessed. Statistical significance will be
defined at the 0.05 level using a two-sided comparative test.
Discussion
This randomised controlled trial of a SMS reminder system
to improve the rate of attendance for follow up oral glucose
tolerance testing in women who have experienced GDM is
important given the high, and rising, rate of GDM, and the
strong association between GDM and subsequent type 2
DM worldwide. In Australia, this is a particularly timely
trial, given the recent establishment of the National Gesta-
tional Diabetes Register, the increasingly ubiquitous use of
mobile phones, and the decreasing use of postal services
(“snail mail”) for communication. Such a reminder system
may prove to be a cost-effective measure to reduce future
rates of type 2 DM in Australian women, and is therefore
of public health as well as obstetric importance. Such a sys-
tem has the potential to be implemented locally or on a
wider scale to improve the health of all women who have
experienced GDM.
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